home / stock / krbp / krbp quote
Last: | $1.45 |
---|---|
Change Percent: | 0.0% |
Open: | $1.58 |
Close: | $1.45 |
High: | $1.58 |
Low: | $1.45 |
Volume: | 12,952 |
Last Trade Date Time: | 09/13/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.45 | $1.58 | $1.45 | $1.58 | $1.45 | 12,952 | 09-13-2023 |
$1.58 | $1.56 | $1.58 | $1.65 | $1.51 | 19,493 | 09-12-2023 |
$1.54 | $1.57 | $1.54 | $1.57 | $1.43 | 22,974 | 09-11-2023 |
$1.52 | $1.52 | $1.52 | $1.5699 | $1.44 | 15,678 | 09-08-2023 |
$1.5701 | $1.6 | $1.5701 | $1.65 | $1.55 | 22,104 | 09-07-2023 |
$1.637 | $1.88 | $1.637 | $1.88 | $1.6 | 40,244 | 09-06-2023 |
$1.87 | $1.8 | $1.87 | $1.91 | $1.57 | 60,947 | 09-05-2023 |
$1.822 | $1.7866 | $1.822 | $2.4 | $1.7797 | 612,931 | 09-04-2023 |
$1.822 | $1.7866 | $1.822 | $2.4 | $1.7797 | 612,931 | 09-01-2023 |
$1.83 | $1.88 | $1.83 | $1.89 | $1.7603 | 18,756 | 08-31-2023 |
$1.8 | $1.88 | $1.8 | $1.9 | $1.77 | 4,279 | 08-30-2023 |
$1.93 | $1.945 | $1.93 | $2 | $1.865 | 7,952 | 08-29-2023 |
$1.93 | $1.79 | $1.93 | $1.93 | $1.79 | 25,894 | 08-28-2023 |
$1.75 | $1.88 | $1.75 | $1.88 | $1.75 | 9,732 | 08-25-2023 |
$1.9 | $1.95 | $1.9 | $1.9844 | $1.9 | 5,525 | 08-24-2023 |
$1.98 | $2.15 | $1.98 | $2.16 | $1.88 | 17,383 | 08-23-2023 |
$2.14 | $2.15 | $2.14 | $2.3199 | $2.12 | 9,137 | 08-22-2023 |
$2.22 | $2.1501 | $2.22 | $2.2727 | $2.1501 | 6,604 | 08-21-2023 |
$2.18 | $2.3 | $2.18 | $2.33 | $2.15 | 43,661 | 08-18-2023 |
$2.33 | $2.2301 | $2.33 | $2.43 | $2.2 | 34,968 | 08-17-2023 |
News, Short Squeeze, Breakout and More Instantly...
Kiromic BioPharma Inc. Company Name:
KRBP Stock Symbol:
NASDAQ Market:
Kiromic BioPharma Inc. Website:
Follow-up Findings Show Stable Disease FDA and IRB Approve IND for a Single-Use, Single-Patient Treatment with Deltacel Fast Track Designation Request Submitted to FDA Complete Enrollment in Trial’s Second Cohort Expected in July Kiromic BioPharma, Inc. ...
Favorable Follow-up Findings Include Stable Disease and a 13% Decrease in Tumor Size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable six-month follow-up results from the first patient enrolled in the Deltacel-01 Phase ...
Scans of this first patient in the second cohort show 8.5% reduction in tumor size Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable safety and tolerability, and early efficacy in the fourth patient enrolled in the Compa...